Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Greenwich Lifesciences Inc GLSI

Healthcare Biotechnology
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a... see more

Recent & Breaking News (NDAQ:GLSI)

Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 13, 2021

Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments

Business Wire September 9, 2021

Greenwich LifeSciences to Participate in Citi's 16th Annual Biopharma Virtual Conference

Business Wire September 7, 2021

Greenwich LifeSciences Set to Join Russell 2000® Index

Business Wire June 8, 2021

Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated

Business Wire June 7, 2021

Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization

Business Wire April 19, 2021

Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting

Business Wire April 14, 2021

REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Business Wire April 12, 2021

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer

Business Wire April 10, 2021

Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up

Business Wire April 9, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI

Newsfile March 24, 2021

Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference

Business Wire March 23, 2021

Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting

Business Wire March 11, 2021

Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour

Business Wire March 10, 2021

Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer

Business Wire March 8, 2021

Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences

Business Wire March 2, 2021

Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference

Business Wire February 25, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Greenwich LifeSciences, Inc.- GLSI

Newsfile February 2, 2021

Greenwich LifeSciences Announces Exercise and Closing of Underwriter's Over-Allotment Option

Business Wire January 29, 2021

Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report

Business Wire January 29, 2021